Gemini Therapeutics Inc.

10.61-0.0600-0.56%Vol 179.20K1Y Perf -10.17%
Jun 16th, 2021 16:00 DELAYED
BID10.70 ASK12.05
Open10.68 Previous Close10.67
Pre-Market- After-Market-
 - -  - -%
Target Price
22.67 
Analyst Rating
— — 0.00
Potential %
113.67 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap456.79M 
Earnings Rating
Price Range Ratio 52W %
22.86 
Earnings Date
12th Aug 2021

Today's Price Range

10.5410.94

52W Range

8.1019.08

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-8.38%
1 Month
0.28%
3 Months
-38.39%
6 Months
-
1 Year
-10.17%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GMTX10.61-0.0600-0.56
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.32-0.59-84.38
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.42
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume179.20K
Shares Outstanding43.05M
Trades Count2.44K
Dollar Volume3.04M
Avg. Volume245.06K
Avg. Weekly Volume139.96K
Avg. Monthly Volume188.94K
Avg. Quarterly Volume257.58K

Gemini Therapeutics Inc. (NASDAQ: GMTX) stock closed at 10.83 per share at the end of the most recent trading day (a -0.56% change compared to the prior day closing price) with a volume of 321.92K shares and market capitalization of 456.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Gemini Therapeutics Inc. CEO is Jason Patrick Meyenburg.

The one-year performance of Gemini Therapeutics Inc. stock is -10.17%, while year-to-date (YTD) performance is %. GMTX stock has a five-year performance of %. Its 52-week range is between 8.1 and 19.08, which gives GMTX stock a 52-week price range ratio of 22.86%

Gemini Therapeutics Inc. currently has a PE ratio of -29.50, a price-to-book (PB) ratio of 2.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -5.34%, a ROC of -11.91% and a ROE of -5.91%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Gemini Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Gemini Therapeutics Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for Gemini Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Gemini Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gemini Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gemini Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.35, ATR14 : 0.92, CCI20 : -108.26, Chaikin Money Flow : -0.08, MACD : -0.14, Money Flow Index : 52.42, ROC : -13.74, RSI : 42.85, STOCH (14,3) : 3.70, STOCH RSI : 0.00, UO : 38.91, Williams %R : -96.30), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gemini Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Gemini Therapeutics Inc.

Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health.

CEO: Jason Patrick Meyenburg

Telephone: +1 617 401-4400

Address: 300 One Kendall Square, Cambridge 02139, MA, US

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

71%29%

Bearish Bullish

50%50%

News

Stocktwits